{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:45:01Z","timestamp":1790023501443,"version":"4.0.1"},"reference-count":33,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Abstract:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Background:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    An anti-interleukin-13 antibody tralokinumab is effective for atopic dermatitis (AD), but its effectiveness on different anatomical sites and clinical signs remains unclear.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Objective:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    To assess the effectiveness of tralokinumab on different anatomical sites and clinical signs of AD.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Methods:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    This study included 129 moderate-to-severe AD patients treated with tralokinumab for 36 weeks. Eczema Area and Severity Index (EASI) scores were analyzed on four anatomical sites (head\/neck, trunk, upper, and lower limbs) and four clinical signs (erythema, edema\/papulation, excoriation, and lichenification) at weeks 0, 4, 12, 24, and 36.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Results:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Tralokinumab consistently reduced EASI scores on 4 anatomical sites and 4 clinical signs. The magnitude of decreasing EASI appeared highest on lower limbs\u3000while the achievement rates of EASI 75 at week 36 on 4 anatomical sites were mostly similar (72.6\u201377.6%). The magnitude of decreasing EASI and achieving EASI 75 or 100 appeared highest for excoriation, and the rates of EASI 75 at week 36 for erythema, excoriation, lichenification and edema\/papulation were 71.1%, 69.4%, 68.4%, and 60.5%, respectively.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Conclusions:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Tralokinumab reduced EASI scores across various anatomical sites and clinical signs in moderate-to-severe AD patients. These findings suggest that tralokinumab may be widely useful for diverse skin manifestations of AD.\n                  <\/jats:p>","DOI":"10.1089\/derm.2024.0538","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:30:22Z","timestamp":1739273422000},"page":"84-90","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Effectiveness of Tralokinumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: A 36-Week Real-World Study"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-9596","authenticated-orcid":false,"given":"Teppei","family":"Hagino","sequence":"first","affiliation":[{"name":"From the,  Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Fujimoto Dermatology Clinic, Funabashi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"From the,  Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.12.646"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.008"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16549"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2019.08.009"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100195"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2021.10.004"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.13954"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000499431"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13160"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1858802"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.018"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2016.12.005"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0627"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00702-2"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20832"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad038"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2023.0030"},{"key":"e_1_3_1_22_2","article-title":"An open-label prospective observational study of tralokinumab in atopic dermatitis patients with inadequate response to dupilumab","author":"Polaskey MT","year":"2024","unstructured":"Polaskey MT, , Fakhraie S, , Daftary K, et al. An open-label prospective observational study of tralokinumab in atopic dermatitis patients with inadequate response to dupilumab. Dermatitis. 2024.","journal-title":"Dermatitis"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2023.0261"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2024.4750"},{"key":"e_1_3_1_25_2","article-title":"Effects of tralokinumab on clinical and laboratory indexes in atopic dermatitis: A 24-week real-world study","author":"Hagino T","year":"2024","unstructured":"Hagino T, , Onda M, , Saeki H, et al. Effects of tralokinumab on clinical and laboratory indexes in atopic dermatitis: A 24-week real-world study. Dermatitis. 2024.","journal-title":"Dermatitis"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.06.009"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2212095"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16763"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2018.06.003"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00421-020-04503-5"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17703"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000590"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16950"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17705"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2024.0538","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2024.0538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2024.0538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:16:18Z","timestamp":1789809378000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/derm.2024.0538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["10.1089\/derm.2024.0538"],"URL":"https:\/\/doi.org\/10.1089\/derm.2024.0538","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}